Fact CheckerSign in

NCT06979076Not yet recruitingPhase 1/2

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Source: ClinicalTrials.gov · Last updated 29 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1/2
Study type
Interventional
Enrollment
12 (estimated)
First submitted
2 May 2025
Start date
Jul 2026
Primary completion date
Sept 2028
Lead sponsor
MingSight Pharmaceuticals, Inc
NCT number
NCT06979076

What you commit to

  • Study type: Interventional · Phase 1/2
  • Planned participants: 12
  • From Jul 2026 to the primary completion date, Sept 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Active and uncontrolled autoimmune cytopenia(s).

Other

  • Current transformation of CLL/SLL non-Hodgkin lymphoma or Hodgkin lymphoma.

Who the study is looking for

  • Age 18 years or older.
  • Diagnosis of CLL or SLL:
    • History of histologically documented CLL or SLL that meets iwCLL diagnostic criteria according to the 2018 guidelines, and
    • Indication for treatment as defined by the 2018 iwCLL guidelines, or the need for disease reduction prior to allogeneic transplantation.-

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.